NCT05841849View on ClinicalTrials.gov

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

1,028

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2029

Conditions

Breast CancerChemotherapy-induced Nausea and Vomiting

Interventions

DRUG

Aprepitant

oral aprepitant capsules 125mg for D1 before chemotherapy, 80mg for D2 and D3

DRUG

Palonosetron

oral palonosetron 0.5mg for D1 before chemotherapy; intravenous palonosetron 0.25mg for D1 before chemotherapy;

DRUG

Fosaprepitant

intravenous fosaprepitant 150mg for D1 before chemotherapy

Trial Locations (1)

Unknown

the Second Affiliated Hospital of Zhejiang Univercity School of Medicine, Hanzhou

All Listed Sponsors

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT05841849 - Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer | Biotech Hunter | Biotech Hunter